Woodline Partners’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.92M Buy
23,653
+20,130
+571% +$6.62M 0.03% 596
2025
Q4
$1.23M Buy
+3,523
New +$1.19M ﹤0.01% 824
2025
Q2
Sell
-131,036
Closed -$57M 962
2025
Q1
$57M Buy
131,036
+128,612
+5,306% +$51.6M 0.37% 69
2024
Q4
$894K Buy
+2,424
New +$1.01M 0.01% 778
2024
Q2
Sell
-57,586
Closed -$29.9M 594
2024
Q1
$29.9M Buy
+57,586
New +$28.6M 0.27% 114
2022
Q3
Sell
-29,410
Closed -$14.2M 775
2022
Q2
$14.2M Buy
+29,410
New +$14.5M 0.22% 144
2020
Q2
Sell
-37,048
Closed -$8.41M 161
2020
Q1
$8.41M Buy
+37,048
New +$10.1M 0.6% 57

Other funds holding ELV

Woodline Partners's ELV Position: Q1 2026 in Review

Woodline Partners increased its Elevance Health (ELV) stake by 571% in Q1 2026, buying an estimated $6.62M and bringing the position to 23,653 shares worth $6.92M. The position accounts for 0.03% of the portfolio, ranked #596.

Woodline Partners first reported a position in ELV in Q1 2020 and has held it in 7 quarters since. The position peaked at $57M in Q1 2025. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Woodline Partners held 23,653 shares of Elevance Health worth $6.92M as of Q1 2026.
  • Woodline Partners bought 20,130 Elevance Health shares in Q1 2026, an estimated $6.62M.
  • Elevance Health made up 0.03% of Woodline Partners's portfolio in Q1 2026, its #596 holding.
  • Woodline Partners first reported a position in Elevance Health in Q1 2020 and has held it in 7 quarters since.
  • Woodline Partners's Elevance Health position peaked at $57M in Q1 2025.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.